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Abstract The critical function of the neurofibromatosis type 1 lyzed, As a clue to elucidate further the function of neurofi- 
(NFI) gene product (neurofibromin) is not well defined except bromin, we directed our attention to reports suggesting that 
that neurofibromin has homology with a family of the GTPase- neurofibromin s heavily phosphorylated on serine and threo- 
activating proteins (GAPs). In this study, we confirmed that nine resiid~ues in response to growth factors [3,18]. In this 
neurofibromin is constitutively phosphorylated and detected study, we detected kinase activities which specifically phos- 
kinase activities which specifically phosphorylate he eysteinl phorylate neurofibromin in cell extracts and defined that 
serine-rich domain and fhe C-terminal domain of the neurofi- cAMP-dependent protein kinase (PKA) is a candidate for 
hromin in cell lysate. In vitro and in-gel kinase assays trongly the neurofibromin kinase. 
indicated that cAMP-dependent protein kinase (PKA) is a 
candidate for the neurofibromin kinase. The biolo,.ical signifi- 
cance of the phosphorylation of neurofibromin is unclear at 
present, but we speculate that neurofibromin plays a crucial role 
in cellular function since it links the two major cellular pathways 
which are the GAP..rns and PKA-assnciated signals. 
Key words: Neurofibromatosis type I (NF1); 
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1. Introduction 
Neurofibromatosis type I (NFI) get~e was identified by po- 
sitional cloning [1,2], and regarded as one of the tumor sup- 
pressor genes [3,4]. Analysis of the predicted protein sequence 
of the NF1 gene product (neurofibromin) revealed that a 360- 
amino acid region in the center of the protein has significant 
homology with a family of the GTPase-activating proteins 
(GAPs) including mammalian ras-GAP, budding yeast IRA1 
and IRA2, fission yea~[-sarl, and Drosophila GAPI [5-8]. 
Neurofibromin has more extensive sequence homology with 
Saccharomyces cerevisiae IRA proteins [9-I 1] than with other 
GAPs. This GAP-related domain of neurofibromin (NF1- 
GRD) has been found to possess GTPase-stimulating activity 
and complement the loss of IRA function in S. cerevisiae, 
indicating that neurofibromin is the mammalian homologue 
of IRA1 and IRA2 [5,12113]. In addition, it has been reported 
that there are two types of NFI-GRD transcripts, type I and 
type II, generated by the alternative splicing mechanism 
[14,15]. The NFI-GRD type II transcript contains an inser- 
tion of 63 nucleotides (21 amino acids) in the center of the 
NF1-GRD region, and the relative abundance of the type I 
versus the type II form is modulated ifferentially during 
brain development and can be affected by stimulation with 
retinoic acid [14]. 
To date, the function of NFI-GRD is fairly well character- 
ized [12,14-17], but that of other domains remains to be ana- 
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2. Materials and methods 
2.1. Cell culture and preparation ofcell extracts 
SH-SY5Y human neuroblastoma cells and SV40-transformed hu-
man fibroblast (VAI3) cells were cultured in a 1:1 mixture of Eagle's 
minimum essential medium (MEM) and Ham's F12 nutrient medium 
supplemented with 5% (v/v) heat-inactivated fetal calf serum in a 
humidified CO2 incubator. Confluently grown SH-SYSY cells and 
VAI3 cells were incubated in serum-free medium for 12 and 48 h, 
respectively, and then treated with 100 nM phorbol 12-myristate 13- 
acetate (PMA) for 15 rain, and 50 taM forskolin for 20 min. VAI3 
cells were also stimulated with 40 nM epidermal growth factor (EGF) 
for 15 rain. After the treatments, the cells were scraped into ice-cold 
extraction buffer consisting of 20 mM Tris (pH 7.4), I0 mM MgCI2, 
5 mM EGTA, 2 mM dithiothreitol, 50 mM [5-glycerophosphate, 
0.1 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 10 I.tg/ml aprotinin, and I0 tag/ml leupeptin. The collected 
cells were lysed by sonication for 10 s, and then centrifuged at 
10O000xg for 3O rain at 4°C. The supernatant was used immeadiately 
as cell extracts. 
2.2~ Plasmid construction 
pGEX-2TH bacterial expression vector and a pGEX-2TH pins- 
mid harboring NFI-GRD type I eDNA which generates GST-GRD 
type I fusion protein (residues 1168-1545) were generously provided 
by Dr. H. Maruta. A GST.GRD type II expression plasmid was 
constructed by ligation of the NFI-GRD type II eDNA [14] into 
the multi-cloning site of the pGEX-2TH vector. Furthermore, we 
generated three other GST-neurofibromin domain fusion proteins cor- 
responding to sequences of residues 543-909,1530-1950, and 2262- 
2818 of neurofibromin, which were tentatively designated cysteine/ser- 
ine-rich domain (CSRD), leucine repeat domain (LRD), and COOH- 
terminal domain (CTD), respectively. The eDNA fragments corre- 
sponding to the various domains were amplified by RT-PCR using 
three sets of oligonucleotide primers that contained appropriate r - 
striction sites flanking the domains of interest (CSRD sense primer 
5'-CAGAGAATI'CCAGGAAGCAATGGAGGCTCTGC-Y, anti- 
sense primer 5'-TTTGAAGCTTCAC'ITI'CTCATGGT'I'ACACAC- 
3'; LRD sense primer 5'-TCCTGGATCCCACAAACCTGTGGCA- 
GATACACA-Y, anti-sense primer 5'-GAATAAGCTTAACTCT- 
TI'GTCGTTrGGCATCAT-Y; CTD sense primer 5'-AAAAA- 
GATCTGACACTTACAACAGTCAAGTT-Y, anti-sense primer 
5'-AAGCAAGCTTCACACGATCTTCTTAATGCTA-Y) and single 
strand eDNA prepared from poly(A) + RNA of SH-SY5Y cells [14]. " 
The amplified DNA fragment was digested by restriction enzymes and 
cloned into the pGEX-2TH plasmid. The entire sequences of the in- 
serts were confirmed to be identical to the previously reported se- 
quences by DNA sequencing analysis. 
All rights reserved. 
, 1000 ~ LR 2000 M M~.2818 aa 
- I os.ol I .o !1 '.o I - |  cTo I 
A AA A A A 
,oo. '°°'N '°°'N 
Fig. I. (A) Schematic representation f the structure of neurofibromin. Five domains of neurofibromin which were generated in bacterial cell as 
GST fusion proteins are demonstrated. CSRD, cysteine/serine-rich domain; GRD, GAP-related domain; LRD, leucine-repeat domain; CTD, 
C-terminal domain. The positions of two insertions generated by the mechanism of alternative splicing (arrowheads), putative cAMP depend- 
ent-protein kinase (PKA) phosphorylation sites (A), MAP kinase phosphorylation sites (M), and the position of leucine repeat (LR) are indi- 
cated. (B) Immunoprecipitates obtained with preimmune serum, anti-CSRD serum, anti-GRD type II serum, NFI GRP(N), and GRP(D) anti- 
bodies from human neuroblastoma (SH-SY5Y) cells were probed with anti-CSRD serum. (C) Lysates of [3SS]methionine-labeled SH-SYSY cells 
were immunopreeipitated with preimmune serum or anti-CSRD serum. (D) Lysates from [a2p]orthophosphate-labeled SH-SY5Y cells were im- 
munoprecipitated with preimmune serum or anti-CSRD serum. The immune comlexes were separated by 6% SDS-PAGE. The positions of mo- 
lecular size markers were shown on the left. 
2.3. Expression attd purification of GST-neurofibrombz domain filsion 
proteins 
Expression and purification of GST-GRD type I fusion protein was 
essentially performed according the original protocol described by 
Smith and Johnson [19]. In the case of other GST fusion proteins, 
the proteins were purified from insoluble fractions according to the 
method escribed by Frangioni and Neel [20]. 
2.4. Generation of rat polyclonal nti-neurofibromin atttibodies 
Antibodies against GST-CSRD and GST-GRD type II fusion pro- 
teins were raised in male Fisher 344 rats. Approximately 100 lag of the 
GST-fusion protein was used to immunize ach rat on a biweekly 
injection schedule. Rats were killed 10 days after the last boost, and 
the sera were collected. The antiserum was preeleared with excess 
GST conjugated glutathione (GSH)-agarose beads (Sigma) before use. 
2.5. hnmunoprecipitation, immunoblotting and metabolic labelhlg 
Confluently grown SH-SY5Y cells were lysed in RIPA buffer con- 
sisting of PBS (pH 7.4) with 1% NP-40, 0.1% SDS, 0.5% sodium 
deoxycholate, 1 mM PMSF, 20 lag/ml aprotinin, and 10 lag/ml eu- 
peptin. The supernatant of the lysate was used for immunopreeipita- 
tion with rat preimmune serum, rat anti-CSRD and anti-GRD type II 
polyclonal antibodies, and commercially available rabbit anti-NFl 
GRP(N) and NFI GRP(D) antibodies (Santa Cruz Biotechnology, 
Inc., CA). The immunoprecipitated proteins were separated by 6% 
SDS-PAGE (Schleicher & Schuell), and transferred onto a nitrocellu- 
lose membrane. The membrane was immunoblotted with anti-CSRD 
antibody, and detected the specific signals by using ECL system 
(Amersham Corp., Arlington Heights, IL). 
For metabolic labeling with [35S]methionine, 60-80% confluent SH- 
SY5Y cells in 60 mm dish were incubated with methionine-free MEM 
. . . . . . . . . . .  % . . . . . . . .  fe . . . . . . . . . . . . . .  d I00 f~C~/TI ! 
[3SS]methionine (Amersham Corp., Arlington Heights, IL) 
For metabolic labeling with [32p]orthophosphate (Amersham Corp., 
Arlington Heights, IL), 60-80% confluent SH-SY5Y cells in 60 mm 
dish were incubated with phosphate-free MEM containing 5% dia- 
lyzed fetal calf serum and 1 mCi/ml [32p]orthophosphte for 4 h. The 
labeled cells were lysates prepared as described above were subjected 
to immunoprecipitation. The immunoprecipitated proteins were sepa- 
rated by 6% SDS-PAGE, followed by autoradiography. 
2.6. hz vitro kinase assay 
Assays were conducted at 25"C for 20 min in a final ~o~ime orS0 p.I 
containing 20 mM Tris (pH 7.4), 10 mM MgCI2,10 laCi of [7-32p]ATP 
(3000 Ci/mmol) (New England Nuclear), 15 lai of cell extracts, and 
5 lag of GST-neurofibromin domain fusion protein with or witllout 
2 laM cAMP-dependent protein kinase (PKA)-inhibitor peptide 
(PKl[6--22]amide, GiBCO-BRL). For the termination 'of reaction 
and separation of phosphorylated GST fusion proteins, each reaction 
mixture was immeadiately chilled and mixed with 60 lal of GSH-agar- 
ose beads (50% slurry) and 1 ml of ice-cold TNE buffer containing 
20 mM Tris (pH 7.4), 1% NP-40, 10 mM EDTA, 100 mM NaCI, 
10 mM NaF, 10 mM 13-glycerophosphate, 1 mM NazVO4, 1 mM 
PMSF, 10 lag/ml aprotinin, and 10 I.tg/ml leupeptin, followed by rock- 
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Fig, 2, Detection of neurofibrornin kinase activities in cell extracts. Control (serum-starved), PMA-, and forskolin-treated VAI3 and SH-SY5Y 
cell extracts and EGF-treated VAI3 cell extracts were incubated for 20 rain at 25°C with each GST-nenrofihromin domain fusion protein and 
[7-32P]ATP in the absence ( - )  and presence (+) of PKA inhibitor (PKI). (A) There was no prominent kinase activity detected in the VAI3 cell 
extracts against GST, GST-GRD type I, GST-GRD type II, and GST-LRD fusion proteins. PKI-scnsitive kinase activities stimulated by for- 
skolin in VA13 cell extracts against GST-CSRD and GST-CTD fnsion proteins were detected. There were PKi.insensifive kinase activities to- 
ward GST-CTD fusion protein in PMA-, EGF-treated VAI3 cell extracts. (B) SH-SY5Y neuroblastoma cell extracts also had both PKI-sensi- 
tive and-insensitive kinase activities toward GST-CSRD and GST-CTD, 
ing for 20 rain at 4°C. The GSH-agarose beads were then washed 10% SDS-polyacrylamide gel prior to polymerization. The gel con- 
three times with TNE buffer, and heated in 30 p] of Lacmrnli sample rained GST (0,5 rng/rn]), GST-CSRD (0.1 rng/rnl), GST-CTD (0.1 
buffer to e]ute the GST fusion proteins. The sample was resolved by rng/ml), or no substrate for each detection, 20 Id of cell extracts 
8-]6% SDS-PAGE. The gel was stained with Coomassie brilliant obtained after several treatments, or 2 I.tl (10 units) of cAMP-depen- 
blue, dried, and radioactive bands were detected by autoradiography, dent protein kinase (PKA) catalytic subunit from bovine heart (Sig- 
rna) was loaded on each lane. After electrophoresis, denaturation with 
2.7. hi-gel kinase assay 6 M guanidine HCI, and renaturation, protein kinase activity was 
Detection of protein kinase activity on polyacrylarnide g ls contain- detected by incubating the gel at 25°C for 60 rain with 40 mM HEPES. 
ing substrate proteins after SDS-PAGE [21] was performed aczording (pH 7.5), 2 mM dithiothreitol, 0.1 mM EGTA, 5 mM MgCI2, 2.5 p.Ci/ 
to the method of Kameshita nd Fujisawa [22]. The substrate for rnl [y-3~P]ATP (3000 Cilmrnol). The incorporation of phosphate was 
phosphorylation by protein kinases in cell extracts was included in then analyzed by autoradiography of the dried gel. 
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Fig. 3. Detection of neurofibromin kinase activities by in-gel kinase assay. VA13 cell extracts and PKA catalytic subunit were electrophoresed 
on a polyacrylamide g l containing no substrate, GST, GST-CSRD fusion protein, or GST-CTD fusion protein. After renaturation of the pro- 
teins in the gels, protein kinase activity was determined using [7-a~P]ATP as described in section 2. Similar results were obtained using SH- 
SYSY cell extracts (data not shown). 
2.8. Phosphorylation f GST.neurofibromin domain fitsion proteh~s and I B and C) which was consistent with the previous reports [25- 
immunoprecipitated n urofibromh~ by PKA catalytic subunit 27]. Neurofibromin was specifically recognized by anti-CSRD 
In vitro kinase reactions tbr the GST-neurofibromin domain fusion and-GRD type II sera as well as NF1 GRP(N) and GRP(D) 
proteins were carried out in a final volume of 50 pl containing 20 mM 
Tris (pH 7.4), 10 mM MgCI~, I0 pCi of [?.3~p] ATP (3000 Ci/mmol), antibodies. Neurofibromin is reported to be a phosphopro- 
5 pg of GST fusion protein with or without I0 units of PKA catalytic tein, in which serine and threonine residues are phosphory- 
subunit at 250C for 20 min. After the reactions, 1 ml of ice-cold TNE lated [I 8]. Our [~2P]orthophosphate l beling experiment also 
buffer and 60 lal of GSH-agarose beads (50% slurry) were added to revealed that neurofibromin is phosphorylated in vivo (Fig. 
each reaction mixture, followed by rocking for 15 rain at 4°C. The 1~). Phosphoamino acid analysis of the phosphorylated neu- 
GST.fusion protein was eluted by boiling for 5 rain in 30 pl of 
Laemmli sample buffer. The samples were separated by 8-16% rofibromin revealed that serine and threonine residues were 
SDS-PAGE, and autoradiography was performed, phosphorylated ( ata not shown). 
For examining the phosphorylation of native neurofibromin by 
PKA catalytic subunit, conftuently grown SH-SY5Y cells (1 x 10 ~) 3.2. Detection ofneuroj%romin kinase activity 
were lysed with 1 ml of RIPA buffer. The lysates were immediately 
incubated with anti-CSRD or rat preimmune s rum for 4 h, and then To identify the celhdar kinases which specifically phosphor- 
with Protein G-agarose beads (Oneogene Science Inc., Manhasset, ylate neurofibromin, we performed in vitro kinase reaction 
NY) for 1 h at 4"C. The beads were washed and resuspended in a using cell extracts as sources of the enzyme and various 
36 pl of solution containing 25 mM sodium acetate, 2 mM MgCI~, GST-neurofibromin domain fusion proteins as the substrates 
and 20 pCi of [?-z~P]ATP (3000 Ci/mmol). Kinase reaction was started (Fig. 2). Among these domains, only CSRD and CTD were 
by adding 20 units of PKA catalytic subunit. After the incubation at 
37°C for 20 rain, the beads were washed and boiled in Laemmli significantly phosphorylated by VAI3 celi extract (Fig. 2A). 
sample buflbr to elute the GST fusion proteins. The sample was sep-  SH-SY5Y neuroblastoma cell extract also phosphorylated 
arated on 4--12% gel, and autoradiography was performed. CSRD and CTD (Fig. 2B). The phosphorylation of CSRD 
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To elucidate the function of neurofibromin, we produced ,~,O ~ ~ .'v O 
five GST-neurofibromin domain fusion proteins. Fig. IA illus- r#  ° 'A" "~' ~° ~'  
. . . . . . .  he domains of . . . . .  fibromin. GRD type II has 21 kDa "~ ~ ~ ¢~ ¢'~ ¢'~ 
amino acid inserts in GRD type I, which are generated by r - - - ' l  r - - - - I  ~ r - ' - ' l  r ' - ' - ' !  r - - - * i  
the mechanism of RNA alternative splicing [14]. CSRD is a 97.4 - : i : i i 
cysteine-and serine-residue-rich domain, in which three cys- 69 -  
teine pairs (residues 622/632, 673/680, and 7141721) may be ~ i 
comparable to one that Maru et al. [23] suggested as the ATP- 46-  . ' . .  . . . .  : .... 
binding domain of BCR protein. LRD has a leucine repeat 
which is present beginning at residue 1834, and not predicted 
to be in an cx-helical conformation due to the presence of 30 -  " 
proline in the middle of the repeat [24]. CTD has two putative 21 - 
MAP kinase phosphorylation sites, and another alternative 
splicing was reported in this region [24]. Marchuk et al. [24] PKA : - + - + - + " + " + " + 
suggested six potential cAMP-dependent protein kinase Fig. 4. In vitro phosphorylation f GST-neurofibromin domain fu- 
sion proteins by PKA catalytic subunit. GST and GSToneurofibro- 
(PKA) phosphorylation sites of neurofibromin (Fig. 1A). min domain fusion proteins were incubated for 20 min at 25°C with 
Neurofibromin was detected by both immunoblot and " [¥-32p]ATP in the absence (-) and presence (+) of PKA catalytic 
munoprecipitation assays as an approx. 250 kDa protein (Fig. subunit as described in the text. 










Fig, 5. Phosphorylation of the immunoprecipitated native ncurofi- 
rom|n by PKA catalytic subunit. Immunoprecipitates obtained 
with preimmune s rum and anti-CSRD serum from SH-SY5Y hu- 
man neuroblastoma cells were incubated for 20 rain at 300C with 
[7-a2PJATP and PKA catalytic subunit as described in section 2. 
was enhanced by the extract of the cells treated with forskolin 
which is an activator of adenylate cyclase, and this reaction 
was inhibited by PKI. This result indicated that PKA is in- 
volved in the phosphorylation f CSRD. The phosphorylation 
of CTD was enhanced not only by the forskolin-treated cell 
extract but also by PMA-or EGF-treated cell extract. How- 
ever, the phosphorylation of CTD by PMA-or EGF-treated 
cell extract was not effectively inhibited by PKI. This finding 
suggested that PMA and EGF treatments induce the other 
kinase activities which phosphorylate CTD protein. 
For further characterization f these neurofibromin kinases, 
we employed in-gel kinase assay (Fig. 3). A protein kinase 
with relative molecular mass of 41 kDa was specifically de- 
tected on both GST-CSRD and GST-CTD substrate gels, 
while it was not found in the absence of substrate or when 
GST was used as substrate. The size of the neurofibromin 
kinase was comparable to that of PKA catalytic subunit, 
and the purified PKA catalytic subunit was actually detected 
to phosphorylate both CSRD and CTD substrate gels at the 
same size as the neurofibromin kinase. In addition, the activ- 
ity of the kinase was not changed by various treatments in- 
eluding PMA, EGF, and forskolin. Since regulatory and cat- 
alytic subunits of PKA were separated on SDS- 
polyacrylamide g ls, the in-gel activity of PKA catalytic sub- 
unit should not change by various treatments without the 
regulatory subunit. These lines of evidence strongly suggested 
that the 41 kDa neurofibromin kinase detected on the sub- 
strate gels is the catalytic subunit of PKA. 
Furthermore, we examined whether PKA catalytic subunit 
can phosphorylate immunoprecipitated native neurofibromin 
as well as the GST fusion proteins. As shown in Fig. 4, GST- 
CSRD and GST-CTD fusion proteins were well phosphory- 
lated by PKA catalytic subunit in vitro whereas other do- 
mains were not. In addition, endogenous neurofibromin that 
was immunoprecipitated by ~xsing anti-CSRD antiserum was 
also phophorylated by PKA catalytic subunit in vitro (Fig. 5). 
Autophosphorylation f GST-neurofibromin domain fusion 
proteins and immunopreeipitated endogenous neurofibromin 
was not detected under the conditions tested. 
In this study, we identified neurofibromin as an approx. 250 
kDa protein on SDS-polyacrylamide g l using rat polyclonal 
antibodies raised against GST.neurofibromin domain fusion 
proteins, and also confirmed that the endogeneous neurofibro- 
min is constitutively phosphorylated on its serine/threonine 
residues. Among the five domains of the neurofibromin which 
we generated in bacterial cells as fusion proteins with GST, 
CSRD and CTD were significantly phosphorylated by PKI- 
sensitive kinase that exists in cell extracts. Moreover, the ki- 
nase activity in the cell extract was enhanced by forskolin 
treatment of the ceils. Any other remarkable kinase activities 
against CSRD and CTD were not detected in serum-starved 
cell extracts. To identify the apparent mass of the neurofibro- 
min kinases, we employed the in-gel kinase assay. A promi- 
nent kinase activity migrating with the electrophoretic mobi- 
lity identical to PKA catalytic subunit was detected on the 
gels containing CSRD and CTD as substrates. Moreover, 
PKA catalytic subunit could indeed phosphorylate CSRD, 
CTD and immunoprecipitated native neurofibromin. Direct 
evidence that PKA phosphorylates neurofibromin in vivo 
has not been obtained thus far [28]. Since the basal phosphor- 
ylation level of neurofibromin s high in the cultured cells, it 
may be difficult o observe the effect of forskolin or dibutyryl 
cAMP on the phosphorylation of neurofibromin in vivo. 
However, our results strongly indicate that PKA is a most 
likely neurofibromin kinase. Additionally, we demonstrated 
the existence of PKI-insensitive kinase activity against CTD 
in PMA-and EGF-stimulated cell extracts, which should be 
further elucidated. 
The functional significance of phosphorylation of neurofi- 
bromin by PKA is still unclear, but we presume that neut'ofi- 
bromin has a fundamental function in cells since it is involved 
in both the GAP-ras signaling pathway and the physiological 
response to intracellular second messenger cAMP. Recently, 
the biochemical link between the second messenger cAMP and 
the ras signaling pathway has been reported [29-33]. Wu et al. 
[33] have suggested that in certain cell types, cAMP prevents 
transmission of signals from ras to Raf-l, possibly due to 
phosphorylation ofRaf-I by PKA, and thus inhibits the acti- 
vation of the MAP kinase cascade. Although a role of neu- 
rofibromin in ras-related signaling pathway has not been 
clearly understood, the biochemical consequence of neurofi- 
bromin phosphorylation by PKA should be taken into ac- 
count in the ras-cAMP connection. 
Phosphorylation of ras-related proteins and their relatives 
as a mechanism of regulation has been tested in a number of 
cases [34], in which rapl/Krev-l/smgp21 has been implicated 
in the cAMP-mediated inhibition of platelet metabolism, and 
appeared to be identical to thrombolamban, a major substrate 
for PKA in the cells [35-38]. Phosphorylation of rapl in re- 
sponse to hormones that elevate intracellular cAMP correlates 
with translocation of rapl from a membrane to a cytosolic 
fraction [37]. In addition, it has been shown that rapl-GAP is 
also phosphorylated by PKA [39]. The rapl/Krev-l/smgp21 
has been .,hown to bind with high affinity to ras-GAP, and 
i~ has be."n suggested that this competition may account for its 
ability to revert the ras-transformed phenotype in 3T3 cells 
[39]. The interaction between rapllKrev-1/smgp21 and GRD 
of neurofibromin has not been fully examined. 
As for the subcellular localization of neurofibromin, there 
have been some controversial pieces of evidence reported. 
Neurofibromin isdemonstrated to reside in both the cytosolic 
and particulate fractions [26,40], in which it may associate 
with tubulin [41,42], smooth endoplasmic reticulum [43], and 
cytoplasmic structures that are distinct from actin or tubulin 
filaments [26]. Gregory et al. [42] suggested sequence similarity 
between a small region of neurofibromin (residues 815-834) 
and two other proteins that associate with microtubules, 
MAP-2 and tau, and hypothesized that phosphorylation f 
this region might regulate the association of neurofibromin 
and microtubules. This putative mierotubule-associated region 
(20 amino acids) resides in CSRD, and contains a consensus 
sequence which can be phosphorylated byPKA (on Ser-818). 
Nordlund et al. [43] demonstrated that neurofibromin was 
associated with smooth vesiculotubular elements and eistemal 
stacks, and with multivesicular bodies in the cell bodies and 
dendrites of neurons of the central nervous ystem (CNS), and 
hypothesized that some, if not all, of the CNS manifestations 
of NFI might result from the aiterd expression of neurofibro- 
min in neurons, perhaps through disruption of Ca 2+ signaling, 
translocation of organelles, or endocytic pathways. 
Since the cloning of the gene defective in NFI, there has 
been remarkable progress in dissecting the mechanism of the 
disease, although the pivotal role of neurofibromin cells is 
still unclear as described above. The cumulative vidence in- 
eluding the presence of GAP activity, the localization of neu- 
rofibromin to the nervous ystem, and the potential phosphor- 
ylation by PI(A and other kinases enables us to infer that 
neurofibromin plays a key role in cell growth and differentia- 
tion, and especially in the cellular process of neurons. There- 
fore, better understanding of the function of neurofibromin 
will provide, the fascinating insights into the intraceilular bio- 
logical network as well as the therapy for NFI and malignant 
tumors. 
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